Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Decode genetics and Pfizer have entered a research collaboration to discover sequence variants in the human genome that are linked with the risk of Systemic Lupus Erythematosis (SLE).
Subscribe to our email newsletter
Under the agreement, which spans over 18 months, the companies will analyse the genomes of patients to search for sequence variants to gain further insights into drug targets.
The research collaboration will utilize Decode’s comprehensive population genetics resources and analytical expertise and Pfizer’s genomic analysis for the discovery and development of drugs.
Decode founder and CEO Kari Stefansson said their research platform would help understand the genetic basis of disease and modifiers of clinical phenotypes in actual patient populations.